Inflammation in Diabetic Nephropathy: Moving Toward Clinical Biomarkers and Targets for Treatment

Overview

Journal Endocrine

Specialty Endocrinology

Date 2014 Oct 3

PMID 25273317

Citations 64

Authors

Federica Barutta

Graziella Bruno

Serena Grimaldi

Gabriella Gruden

Affiliations

Soon will be listed here.

Abstract

Diabetic nephropathy (DN) is a leading cause of end stage renal failure and there is an urgent need to identify new clinical biomarkers and targets for treatment to effectively prevent and slow the progression of the complication. Many lines of evidence show that inflammation is a cardinal pathogenetic mechanism in DN. Studies in animal models of experimental diabetes have demonstrated that there is a low-grade inflammation in the diabetic kidney. Both pharmacological and genetic strategies targeting inflammatory molecules have been shown to be beneficial in experimental DN. In vitro studies have cast light on the cellular mechanisms whereby diabetes triggers inflammation and in turn inflammation magnifies the kidney injury. Translation of this basic science knowledge into potential practical clinical applications is matter of great interest for researchers today. This review focuses on key pro-inflammatory systems implicated in the development of DN: the tumor necrosis factor(TNF)-α/TNF-α receptor system, the monocyte chemoattractant protein-1/CC-chemokine receptor-2 system, and the Endocannabinoid system that have been selected as they appear particularly promising for future clinical applications.

Citing Articles

Mechanisms, Biomarkers, and Treatment Approaches for Diabetic Kidney Disease: Current Insights and Future Perspectives.

Joumaa J, Raffoul A, Sarkis C, Chatrieh E, Zaidan S, Attieh P J Clin Med. 2025; 14(3).

PMID: 39941397 PMC: 11818458. DOI: 10.3390/jcm14030727.

Khayal E, Elhadidy M, Alnasser S, Morsy M, Farag A, El-Nagdy S Toxicol Rep. 2025; 14():101882.

PMID: 39850515 PMC: 11755029. DOI: 10.1016/j.toxrep.2024.101882.

Monocyte to high-density lipoprotein cholesterol ratio as a marker of the presence and progression of diabetic kidney disease.

Yang W, Zhong Y, Zhou P, Lu D Ren Fail. 2025; 47(1):2438846.

PMID: 39806776 PMC: 11734387. DOI: 10.1080/0886022X.2024.2438846.

Higher density of CD4+ T cell infiltration predicts severe renal lesions and renal function decline in patients with diabetic nephropathy.

Han Q, Xu H, Li L, Lei S, Li Z, Zhao L Front Immunol. 2024; 15:1474377.

PMID: 39654881 PMC: 11625791. DOI: 10.3389/fimmu.2024.1474377.

The Potential of Anti-Inflammatory DC Immunotherapy in Improving Proteinuria in Type 2 Diabetes Mellitus.

Jonny J, Sitepu E, Lister I, Chiuman L, Putranto T Vaccines (Basel). 2024; 12(9).

PMID: 39340004 PMC: 11435532. DOI: 10.3390/vaccines12090972.

References

Han J, Thompson P, Beutler B . Dexamethasone and pentoxifylline inhibit endotoxin-induced cachectin/tumor necrosis factor synthesis at separate points in the signaling pathway. J Exp Med. 1990; 172(1):391-4. PMC: 2188134. DOI: 10.1084/jem.172.1.391. View

Awad A, Kinsey G, Khutsishvili K, Gao T, Bolton W, Okusa M . Monocyte/macrophage chemokine receptor CCR2 mediates diabetic renal injury. Am J Physiol Renal Physiol. 2011; 301(6):F1358-66. PMC: 3233863. DOI: 10.1152/ajprenal.00332.2011. View

Matsui T, Yamagishi S, Takeuchi M, Ueda S, Fukami K, Okuda S . Nifedipine, a calcium channel blocker, inhibits advanced glycation end product (AGE)-elicited mesangial cell damage by suppressing AGE receptor (RAGE) expression via peroxisome proliferator-activated receptor-gamma activation. Biochem Biophys Res Commun. 2009; 385(2):269-72. DOI: 10.1016/j.bbrc.2009.05.061. View

Hruby Z, Beck K . Cytotoxic effect of autocrine and macrophage-derived nitric oxide on cultured rat mesangial cells. Clin Exp Immunol. 1997; 107(1):76-82. PMC: 1904549. DOI: 10.1046/j.1365-2249.1997.d01-906.x. View

Nathan D, Genuth S, Lachin J, Cleary P, Crofford O, Davis M . The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993; 329(14):977-86. DOI: 10.1056/NEJM199309303291401. View

Sugimoto H, Shikata K, Wada J, Horiuchi S, Makino H . Advanced glycation end products-cytokine-nitric oxide sequence pathway in the development of diabetic nephropathy: aminoguanidine ameliorates the overexpression of tumour necrosis factor-alpha and inducible nitric oxide synthase in diabetic rat.... Diabetologia. 1999; 42(7):878-86. DOI: 10.1007/s001250051241. View

Wang Y, Chen J, Chen L, Tay Y, Rangan G, Harris D . Induction of monocyte chemoattractant protein-1 in proximal tubule cells by urinary protein. J Am Soc Nephrol. 1997; 8(10):1537-45. DOI: 10.1681/ASN.V8101537. View

McCormick B, Sydor A, Akbari A, Fergusson D, Doucette S, Knoll G . The effect of pentoxifylline on proteinuria in diabetic kidney disease: a meta-analysis. Am J Kidney Dis. 2008; 52(3):454-63. DOI: 10.1053/j.ajkd.2008.01.025. View

Han S, So G, Jee Y, Han K, Kang Y, Kim H . Effect of retinoic acid in experimental diabetic nephropathy. Immunol Cell Biol. 2004; 82(6):568-76. DOI: 10.1111/j.1440-1711.2004.01287.x. View

10.

Okada S, Shikata K, Matsuda M, Ogawa D, Usui H, Kido Y . Intercellular adhesion molecule-1-deficient mice are resistant against renal injury after induction of diabetes. Diabetes. 2003; 52(10):2586-93. DOI: 10.2337/diabetes.52.10.2586. View

11.

Duerr G, Heinemann J, Suchan G, Kolobara E, Wenzel D, Geisen C . The endocannabinoid-CB2 receptor axis protects the ischemic heart at the early stage of cardiomyopathy. Basic Res Cardiol. 2014; 109(4):425. DOI: 10.1007/s00395-014-0425-x. View

12.

Qi W, Chen X, Polhill T, Sumual S, Twigg S, Gilbert R . TGF-beta1 induces IL-8 and MCP-1 through a connective tissue growth factor-independent pathway. Am J Physiol Renal Physiol. 2005; 290(3):F703-9. DOI: 10.1152/ajprenal.00254.2005. View

13.

Okamoto M, Fuchigami M, Suzuki T, Watanabe N . A novel C-C chemokine receptor 2 antagonist prevents progression of albuminuria and atherosclerosis in mouse models. Biol Pharm Bull. 2012; 35(11):2069-74. DOI: 10.1248/bpb.b12-00528. View

14.

Gruden G, Setti G, Hayward A, Sugden D, Duggan S, Burt D . Mechanical stretch induces monocyte chemoattractant activity via an NF-kappaB-dependent monocyte chemoattractant protein-1-mediated pathway in human mesangial cells: inhibition by rosiglitazone. J Am Soc Nephrol. 2005; 16(3):688-96. DOI: 10.1681/ASN.2004030251. View

15.

Ikezumi Y, Suzuki T, Karasawa T, Kawachi H, Nikolic-Paterson D, Uchiyama M . Activated macrophages down-regulate podocyte nephrin and podocin expression via stress-activated protein kinases. Biochem Biophys Res Commun. 2008; 376(4):706-11. DOI: 10.1016/j.bbrc.2008.09.049. View

16.

Gohda T, Niewczas M, Ficociello L, Walker W, Skupien J, Rosetti F . Circulating TNF receptors 1 and 2 predict stage 3 CKD in type 1 diabetes. J Am Soc Nephrol. 2012; 23(3):516-24. PMC: 3294299. DOI: 10.1681/ASN.2011060628. View

17.

Thomas M . Emerging drugs for managing kidney disease in patients with diabetes. Expert Opin Emerg Drugs. 2013; 18(1):55-70. DOI: 10.1517/14728214.2013.762356. View

18.

Matsui T, Yamagishi S, Ueda S, Nakamura K, Imaizumi T, Takeuchi M . Telmisartan, an angiotensin II type 1 receptor blocker, inhibits advanced glycation end-product (AGE)-induced monocyte chemoattractant protein-1 expression in mesangial cells through downregulation of receptor for AGEs via peroxisome.... J Int Med Res. 2007; 35(4):482-9. DOI: 10.1177/147323000703500407. View

19.

Pawluczyk I, Harris K . Macrophages promote prosclerotic responses in cultured rat mesangial cells: a mechanism for the initiation of glomerulosclerosis. J Am Soc Nephrol. 1997; 8(10):1525-36. DOI: 10.1681/ASN.V8101525. View

20.

McKenzie J, Ridley A . Roles of Rho/ROCK and MLCK in TNF-alpha-induced changes in endothelial morphology and permeability. J Cell Physiol. 2007; 213(1):221-8. DOI: 10.1002/jcp.21114. View